Cpds were able to induce ABCA1 and cholesterol efflux from cholesterol-repleted podocytes in vitro and decreased proteinuria, attenuated kidney function decline and prolonged lifespan in mouse models of AS and FSGS, even when the Cpds were administered in mice with established CKD and proteinuria. This evidence concerns the gene ABCA1 and focal segmental glomerulosclerosis.